Traders Purchase Large Volume of Iovance Biotherapeutics Call Options (NASDAQ:IOVA)

Posted by Brenda Bartman on Aug 6th, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) was the recipient of unusually large options trading on Thursday. Stock traders acquired 15,896 call options on the company. This represents an increase of approximately 64% compared to the typical volume of 9,706 call options.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IOVA shares. Chardan Capital reduced their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.43.

View Our Latest Research Report on IOVA

Iovance Biotherapeutics Stock Performance

Shares of NASDAQ IOVA traded up $1.63 during midday trading on Thursday, reaching $5.97. The company’s stock had a trading volume of 32,090,455 shares, compared to its average volume of 15,203,536. The business’s 50 day moving average price is $4.32 and its two-hundred day moving average price is $3.75. The company has a market cap of $2.67 billion, a P/E ratio of -6.33 and a beta of 0.71. Iovance Biotherapeutics has a fifty-two week low of $1.76 and a fifty-two week high of $6.39.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $198.63 million during the quarter, compared to analysts’ expectations of $87.83 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The business’s revenue for the quarter was up 65.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.33) EPS. Sell-side analysts forecast that Iovance Biotherapeutics will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in IOVA. Vanguard Group Inc. grew its stake in shares of Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after buying an additional 3,148,096 shares during the last quarter. State Street Corp raised its holdings in Iovance Biotherapeutics by 51.5% during the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after purchasing an additional 6,851,486 shares during the last quarter. Invenomic Capital Management LP boosted its stake in shares of Iovance Biotherapeutics by 13.5% in the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock valued at $32,649,000 after purchasing an additional 1,417,897 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Iovance Biotherapeutics by 30.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock valued at $23,499,000 after buying an additional 2,032,062 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Iovance Biotherapeutics by 16.4% during the fourth quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock valued at $21,821,000 after buying an additional 1,123,337 shares during the last quarter. 77.03% of the stock is owned by institutional investors.

About Iovance Biotherapeutics

(Get Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.